Lixte股票因先导药物LB-100的临床前数据而飙升

Shares of Lixte Biotechnology (NASDAQ:LIXT) were up nearly 60% in afternoon trading Wednesday after the company reported the publication of positive preclinical data for its lead clinical asset LB-100.

Lixte stock recently sold for $3.58 per share at around 2:35 p.m. ET after hitting a session high of $4.40 earlier in the day.

Lixte said the data showed that LB-100 “can force cancer cells to give up their cancer-causing properties." The data was published online Wednesday by Cancer Discovery and will appear in the periodical’s print edition in July.